HUMA
Humacyte, Inc.
Biotechnology · Healthcare · United States
0.41
close · 2026-10-30
value
3
cheaper than peers3
quality
5
stronger fundamentals5
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 3.64× | 47 |
| earnings yield, 3 years ago | -29.2% | 40 |
| price to sales | 53.86× | 22 |
| earnings yield, latest year | -63.2% | 16 |
| cash flow yield, 2 years ago | -66.2% | 16 |
| cash flow yield, 3 years ago | -63.2% | 15 |
| cash flow yield, latest year | -92.7% | 10 |
| cash flow yield, 1 year ago | -87.3% | 9 |
| earnings yield, 2 years ago | -260.2% | 8 |
| earnings yield, 1 year ago | -306.4% | 5 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 34.9% | 59 |
| debt to equity | 213.9% | 12 |
| return on equity | -547.9% | 2 |
| operating margin | -6649.3% | 2 |
4 of 4 measures available
Facts
| market cap | $114M |
| free cash flow | -$58.4M |
| employees | 184 |
| first trade | 2020-12-01 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.26 | -1.26 | -1.07 | -0.12 |
| free cash flow | -$105.9M | -$99.7M | -$75.6M | -$72.2M |
| net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M |
| revenue | $2.0M | $0 | $0 | $0 |
| unusual items | $76.0M | -$29.1M | -$9.6M | $76.2M |